Limelight Bio emerges with $75m to develop next generation gene therapies to overcome limitations of current treatments

This article was originally published here

Founded in 2017, Limelight Bio has developed proprietary technologies, advanced targets and leading drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches.

The post Limelight Bio emerges with $75m to develop next generation gene therapies to overcome limitations of current treatments appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply